CD57+CD4+ T cells were 17.82% (6.68%-32.1%), 10.48% (3.98%-25.9%), 13.28% (5.26%-41.1%) in HCC, PDA and CCA, respectively, and CD57+ CD8+ T cells were 37.81% (24.83%-56.21%), 33.03% (11.67%-60.35%), 18.17% (16.83%-58.52%) in HCC, PDA and CCA respectively (Figures 1B, C). This evidence concerns the gene CD4 and hepatocellular carcinoma.